Last Posted: Jul 19, 2018
- TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib.
Wang Wen-Xian et al. Journal of thoracic disease 2018 May 10(5) 2991-2998 - Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
et al. JAMA oncology 2018 Jul e182078 - Richard Smith: Is precision medicine a fantasy?
R Smith, BMJ, July 13, 2018 - A decade in psychiatric GWAS research.
Horwitz Tanya et al. Molecular psychiatry 2018 Jun - Diagnosing Lung Cancer: The Complexities of Obtaining a Tissue Diagnosis in the Era of Minimally Invasive and Personalised Medicine.
McLean Anna E B et al. Journal of clinical medicine 2018 Jun 7(7) - Genomic underpinnings of lifespan allow prediction and reveal basis in modern risks
TR Timmers et al, BioRXIV, July 2018 - Osimertinib effective in EGFR T790M-positive lung cancer.
Mayor Susan et al. The Lancet. Oncology 2017 18(1) e9 - Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
Abbosh Christopher et al. Nature reviews. Clinical oncology 2018 Jul - Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.
Aredo Jacqueline V et al. Current treatment options in oncology 2018 Jun 19(8) 43 - Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing Changwen et al. Molecular medicine reports 2018 Jun
.png)
No hay comentarios:
Publicar un comentario